Severe hypersensitivity allergic reaction to filgrastim in a healthy stem cell donor

Introduction Granulocyte–colony stimulating factor (G-CSF) has been approved for use for mobilization of hematopoietic progenitor cells from the marrow into the blood for peripheral blood stem cell collection. Commonly reported side effects of G-CSF include deep throbbing bone pain, severe myalgia a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2019-12, Vol.25 (8), p.2056-2058
Main Authors: Doval, Divya, Choudhary, Dharma, Sharma, Sanjeev K, Khandelwal, Vipin
Format: Article
Language:English
Subjects:
Adult
Anaphylactoid reactions
Anaphylaxis
Bone marrow
Bone marrow transplantation
Chemotherapy
Colony-stimulating factor
Drug Hypersensitivity - etiology
Filgrastim - administration & dosage
Filgrastim - adverse effects
Granulocyte colony-stimulating factor
Hematopoietic Stem Cell Mobilization
Hematopoietic stem cells
Hematopoietic Stem Cells - cytology
Humans
Hypersensitivity
Leukocytes (granulocytic)
Male
Myalgia
Pain - chemically induced
Peripheral blood
Progenitor cells
Sickle cell disease
Stem cell transplantation
Stem cells
Steroid hormones
Steroids
Tissue Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Granulocyte–colony stimulating factor (G-CSF) has been approved for use for mobilization of hematopoietic progenitor cells from the marrow into the blood for peripheral blood stem cell collection. Commonly reported side effects of G-CSF include deep throbbing bone pain, severe myalgia and leucocytosis. Case report We describe a case of severe hypersensitivity anaphylactoid reaction after filgrastim administration in a healthy stem cell donor. This haploidentical donor was a 38-year old man with sickle cell trait, donating stem cells for his son, a case of sickle cell disease. On administration of G-CSF (10 µg/kg) he developed features of anaphylaxis. Management and outcome He was given supportive care with oxygen, IV fluid bolus, anti histaminics and steroids. The donor had complete recovery and underwent successful bone marrow harvest. Conclusion There have been various reports of hypersensitivity anaphylactoid reactions in patients undergoing chemotherapy but those associated with the first dose of G-CSF in healthy stem cell donors have rarely been reported.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155219856419